Phase 3 N=86 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Recurrent Pericarditis
Primary: Time to Pericarditis Recurrence in the RW Period — NA; 8.6 weeks — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 A Pilot Study of KPL-914 in Recurrent Pericarditis
Recurrent Pericarditis
Primary: Parts 1, 2 and 4: Pretreatment C-Reactive Protein (CRP) Levels — 5.921; 0.645; 4.455; 5.156 mg/dL
Phase 2 N=27 Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Recurrent Pericarditis
Primary: 11-point NRS Pain Score — -3.7 units on a scale
Phase 4 N=280 Anti-inflammatory Effects of Colchicine in PCI
Coronary Artery Disease
Primary: Percent Change in Post-procedural IL-6 Concentration From Baseline to 30 Min -1 hr After PCI — 0; 20 % change — p=0.31
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
Phase 4 N=714 Colchicine in Percutaneous Coronary Intervention
Coronary Artery Disease · Acute Coronary Syndrome
Primary: Number of Participants With Peri-procedural Myocardial Necrosis — 118; 122 Participants — p=<0.05
N/A N=96 Remote Ischemic Preconditioning in ad Hoc Percutaneous Coronary Interventions
Coronary Artery Disease
Primary: Delta Cardiac Troponin I (ΔcTnI) — 0.04; 0.19 ng/mL
N/A N=626 Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI
Post Procedural Myocardial Infarction
Primary: Peri-Procedural Myocardial Injury — 23; 29 Participants
N/A N=5,269 Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Myocardial Ischemia · Rheumatic Diseases
Primary: Proportion of Days Covered (PDC) — 82.6; 75.6; 78.4; 73.3 percentage of days covered
Phase 2 N=36 Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Stable Angina
Primary: Number of Participants With Elevation of Cardiac Enzyme — 4; 2 Participants
N/A N=706 Prediction of Recurrent Events With 18F-Fluoride
Coronary Artery Disease · Myocardial Infarction
Primary: Cardiac Death, Non-fatal Recurrent Myocardial Infarction or Unscheduled Coronary Revascularisation — 51; 90 Participants — p=0.20
Phase 3 N=4,745 Colchicine Cardiovascular Outcomes Trial (COLCOT)
Coronary Artery Disease · Myocardial Infarction
Primary: First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute Myocardial Infarction, Stroke, or Urgent Hospitalization for Angina Requiring Coronary…
Phase 3 N=2,651 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease · Angina Pectoris
Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…
N/A N=1,420 Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)
Coronary Disease
Primary: Proportion of Subjects With Device Related Adverse Events. — 0 Proportion of subjects
Phase 2 N=26 Colchicine and CRP in Atrial Fibrillation and AF Ablation
Atrial Fibrillation
Primary: Change in C-reactive Protein — 6.4; 2.7; 2.9; 5.9 ng/mL — p=0.038
Phase 4 N=49 APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Myocardial Infarction
Primary: 6-month Reocclusion — 1; 4 participants
Phase 4 N=28 Ranolazine in Ischemic Cardiomyopathy
Cardiomyopathy · Chest Pain · Dyspnea
Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058
N/A N=186 STOP Persistent AF
Atrial Fibrillation
Primary: Percent of Subjects Free From Treatment Failure at 12 Months After the Pulmonary Vein Isolation (PVI) Ablation Procedure. — 54.8 percentage of participants — p=<0.001
Phase 2 N=30 Anakinra to Prevent Adverse Post-infarction Remodeling (2)
Acute Myocardial Infarction · Heart Failure
Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05
N/A N=105 Randomized Investigation of Chest Pain Diagnostic Strategies
Acute Coronary Syndrome · Chest Pain
Primary: The Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days. — 7; 20 participants
N/A N=3,000 Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Resulting in Myocardial Infarction
Myocardial Infarction · Acute Coronary Syndrome · Coronary Artery Disease
Primary: The Sensitivity and Specificity of ECG for Acute Coronary Occlusion. — 767; 282; 16 Participants
N/A N=266 Remote Ischemic Postconditioning in Humans
Myocardial Reperfusion Injury
Primary: Maximum Increase of Troponin at 24 Hours — 0.478; 0.476 ng/ml
N/A N=312 CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction
Acute Myocardial Infarction
Primary: ECG-documented Ventricular Fibrillation or Symptomatic Sustained Ventricular Tachycardia (VT) — 25; 8; 3; 2 participants
N/A N=10,003 PROspective Multicenter Imaging Study for Evaluation of Chest Pain
Chest Pain
Primary: Time to Primary Endpoint — 1.0; 1.1; 1.2; 1.4 Percentage of participants with an event
Phase 2 N=6 Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
Ventricular Premature Complexes · Myocardial Ischemia
Primary: The Effect of Ranolazine on the PVC Burden Over 30 Days — 5.71; 5.495 percentage of PVC burden
N/A N=20 Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia
Chest Pain
Primary: Capsaicin Sensitivity — 2.05 score on a scale
N/A N=101 Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants With Ulcer Recurrence — 1; 7 participants
N/A N=40 Is Non-Cardiac Chest Pain Caused by Sustained Longitudinal Smooth Muscle Contraction?
Chest Pain Atypical Syndrome
Primary: Mean Change in Esophageal Length With Acid — -0.40; -0.39 centimeters
Phase 2 N=140 Polypill in Acute Coronary Syndrome
Acute Coronary Syndrome · Lipid Disorder · Coronary Artery Disease
Primary: Low Density Lipoprotein - Cholesterol — -6.74; 0.53 mg/dL — p=0.27
N/A N=980 Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial
Cryptogenic Stroke
Primary: Composite of Recurrent Nonfatal Ischemic Stroke, Fatal Ischemic Stroke, or Early Death After Randomization — 9; 16 Participants — p=0.08